We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

DxS and Epigenomics Cross-License Technology for in vitro Diagnostics

DxS and Epigenomics Cross-License Technology for in vitro Diagnostics

DxS and Epigenomics Cross-License Technology for in vitro Diagnostics

DxS and Epigenomics Cross-License Technology for in vitro Diagnostics

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "DxS and Epigenomics Cross-License Technology for in vitro Diagnostics"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

DxS Ltd. and Epigenomics AG have announced that they have cross-licensed certain technologies enabling both companies to develop and commercialize in vitro diagnostic (IVD) products based on DNA methylation that utilize DxS’ proprietary Scorpions technology.

The cross-licensing follows a strategic agreement signed by both companies in January 2008. Under the terms of this agreement, Epigenomics had obtained worldwide non-exclusive rights to DxS’ Scorpions technology for R&D use and research kits, as well as an option to expand the license to the in vitro diagnostics field.

In return, DxS received an option for a worldwide non-exclusive research and IVD license to certain Epigenomics IP covering the use of Scorpions technology for DNA methylation applications. Both companies have now executed their options as granted in last year's agreement and have acquired the right to sub-license their respective licensed technologies.

Dr Stephen Little, CEO of DxS, explained the unique properties of DxS’ standalone technology: “Our Scorpions technology is ideally suited for IVD applications using real-time PCR instrumentation. “The probes are highly sensitive, sequence-specific molecules containing a PCR primer covalently linked to a probe. Scorpion probes can provide strong fluorescent signals, excellent sequence discrimination, short reaction times, and predictable probe design. We believe that this technology is ideal for DNA methylation-based IVD products, particularly in oncology.”

“With Scorpions technology we have complemented our broad technology portfolio for DNA methylation analysis. This expands our area of freedom to operate and give us maximum flexibility in the final product design and testing platforms for cancer molecular diagnostic products directly commercialized by ourselves as well as by our partners”, commented Geert Nygaard, Chief Executive Officer of Epigenomics.

Financial terms of the agreement were not disclosed.